239 related articles for article (PubMed ID: 28164410)
1. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
2. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible KDM3A addiction in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Takahashi N; Tagawa H
Blood Adv; 2018 Feb; 2(4):323-334. PubMed ID: 29444873
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
5. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
6. [Identification of hypoxia-specific therapeutic targets in multiple myeloma].
Ikeda S
Rinsho Ketsueki; 2021; 62(4):305-313. PubMed ID: 33967156
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
Ikeda S; Abe F; Matsuda Y; Kitadate A; Takahashi N; Tagawa H
Cancer Sci; 2020 Nov; 111(11):4088-4101. PubMed ID: 32790954
[TBL] [Abstract][Full Text] [Related]
9. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
10. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Umezu T; Tadokoro H; Azuma K; Yoshizawa S; Ohyashiki K; Ohyashiki JH
Blood; 2014 Dec; 124(25):3748-57. PubMed ID: 25320245
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
[TBL] [Abstract][Full Text] [Related]
12. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
13. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.
Gupta N; Kumar R; Seth T; Garg B; Sharma A
RNA Biol; 2020 Jan; 17(1):98-111. PubMed ID: 31532704
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer.
He C; Wang L; Zhang J; Xu H
Mol Cancer; 2017 Feb; 16(1):35. PubMed ID: 28173803
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Storti P; Toscani D; Airoldi I; Marchica V; Maiga S; Bolzoni M; Fiorini E; Campanini N; Martella E; Mancini C; Guasco D; Ferri V; Donofrio G; Aversa F; Amiot M; Giuliani N
Haematologica; 2016 Mar; 101(3):e107-10. PubMed ID: 26659917
[No Abstract] [Full Text] [Related]
16. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.
Low MSY; Brodie EJ; Fedele PL; Liao Y; Grigoriadis G; Strasser A; Kallies A; Willis SN; Tellier J; Shi W; Gabriel S; O'Donnell K; Pitt C; Nutt SL; Tarlinton D
Cell Rep; 2019 Nov; 29(9):2634-2645.e5. PubMed ID: 31775034
[TBL] [Abstract][Full Text] [Related]
17. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
18. The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis.
Kocemba KA; van Andel H; de Haan-Kramer A; Mahtouk K; Versteeg R; Kersten MJ; Spaargaren M; Pals ST
Leukemia; 2013 Aug; 27(8):1729-37. PubMed ID: 23478664
[TBL] [Abstract][Full Text] [Related]
19. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
Morelli E; Leone E; Cantafio ME; Di Martino MT; Amodio N; Biamonte L; Gullà A; Foresta U; Pitari MR; Botta C; Rossi M; Neri A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Leukemia; 2015 Nov; 29(11):2173-83. PubMed ID: 25987254
[TBL] [Abstract][Full Text] [Related]
20. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
